Sacituzumab Govitecan
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Sacituzumab Govitecan |
| DrugBank ID | DB12893 |
| Brand Names (EU) | Trodelvy |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.78% |
Approved Indication (EMA)
Trodelvy as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic triple-negative breast cancer (mTNBC) who have received two or more prior systemic therapies, including at least one of them for advanced disease.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | drug-induced osteoporosis | 99.78% | DL |
| 2 | severe nonproliferative diabetic retinopathy | 99.69% | DL |
| 3 | diabetic retinopathy | 99.60% | DL |
| 4 | diabetic cataract | 99.12% | DL |
| 5 | cortical cataract | 98.55% | DL |
| 6 | nuclear senile cataract | 98.55% | DL |
| 7 | senile cataract | 98.52% | DL |
| 8 | diabetes mellitus type 2 associated cataract | 98.40% | DL |
| 9 | immature cataract | 98.40% | DL |
| 10 | tetanic cataract | 98.40% | DL |
| 11 | craniostenosis cataract | 98.40% | DL |
| 12 | mature cataract | 98.40% | DL |
| 13 | respiratory syncytial virus infectious disease | 97.82% | DL |
| 14 | dry eye syndrome | 97.49% | DL |
| 15 | hemorrhagic disease of newborn | 97.45% | DL |
| 16 | non-syndromic visceral malformation | 97.39% | DL |
| 17 | non-seminomatous lesion | 97.33% | DL |
| 18 | ductal or ductular proliferation | 97.33% | DL |
| 19 | bronchial adenomas/carcinoids childhood | 97.33% | DL |
| 20 | chondroid hamartoma | 97.33% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.